Angiocrine Bioscience
Angiocrine Bioscience, Inc., with headquarters in San Diego, CA, is a private biopharmaceutical company pioneering the development of engineered endothelial cell-based therapies. The first experimental therapy product, AB-110, entered Phase 1b clinical testing in 1H 2018 involving patients with life-threatening blood malignancies. Angiocrine is rapidly advancing a broad pre-clinical pipeline for multiple indications: multi-organ regeneration post high-dose cancer therapy, lung regeneration and tendon reconstruction; research stage projects include investigative work in stem cell generation and, cardiac and neurological regeneration. Angiocrine has built a robust IP portfolio generated by the Company and also from key technologies licensed from Cornell University.
